Clinical Trial Update: Ph2 Nab-paclitaxel With Gemcitabine to Determine Efficacy in Advanced Non-squamous NSCLC. [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating nab-paclitaxel combined with gemcitabine for advanced non-small cell lung cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Abraxane (paclitaxel albumin-bound)
• Gemzar (gemcitabine)

Snippet

Sponsor: West Virginia University | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: WITHDRAWN